Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
38
CLRB Quote, Financials, Valuation and Earnings
Last price:
$3.20
Seasonality move
:
3.11%
Day range:
$3.15 - $3.65
52-week range:
$2.45 - $20.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
137.94x
P/B ratio:
0.78x
Volume:
97.7K
Avg. volume:
62.2K
1-year change:
-69.32%
Market cap:
$5.8M
Revenue:
--
EPS (TTM):
-$6.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
-- | -$1.22 | -- | -20.45% | $47.00 |
|
IMNN
Imunon, Inc.
|
-- | -$1.34 | -- | -63.28% | $64.47 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PAVM
PAVmed, Inc.
|
-- | -$4.50 | -100% | -78.99% | $9.50 |
|
PDSB
PDS Biotechnology Corp.
|
-- | -$0.20 | -- | -4.94% | $7.50 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
$3.22 | $47.00 | $5.8M | -- | $0.00 | 0% | 137.94x |
|
IMNN
Imunon, Inc.
|
$3.95 | $64.47 | $8.4M | -- | $0.00 | 0% | 16.43x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$7.39 | $0.85 | $931.2M | 12.41x | $0.80 | 0% | 14.36x |
|
PAVM
PAVmed, Inc.
|
$6.98 | $9.50 | $6.4M | 0.30x | $0.00 | 0% | 3,260.80x |
|
PDSB
PDS Biotechnology Corp.
|
$0.91 | $7.50 | $49.7M | -- | $0.00 | 0% | -- |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
4.4% | -1.028 | 3.58% | 2.56x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.037 | 10.13% | 1.25x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
PAVM
PAVmed, Inc.
|
20.6% | -0.512 | 34.03% | 0.30x |
|
PDSB
PDS Biotechnology Corp.
|
65.52% | 0.324 | 37.29% | 1.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
-$52.3K | -$4.9M | -154.34% | -160.56% | -- | -$4.3M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PAVM
PAVmed, Inc.
|
-$72K | -$4.8M | 4.06% | 8.75% | -96880% | -$899K |
|
PDSB
PDS Biotechnology Corp.
|
-$15.1K | -$8.1M | -91.45% | -196.47% | -- | -$5.9M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Cellectar Biosciences, Inc. vs. Competitors
-
Which has Higher Returns CLRB or IMNN?
Imunon, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of --. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About CLRB or IMNN?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1359.63%. On the other hand Imunon, Inc. has an analysts' consensus of $64.47 which suggests that it could grow by 1532.09%. Given that Imunon, Inc. has higher upside potential than Cellectar Biosciences, Inc., analysts believe Imunon, Inc. is more attractive than Cellectar Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 IMNNImunon, Inc.2 1 0 -
Is CLRB or IMNN More Risky?
Cellectar Biosciences, Inc. has a beta of 0.325, which suggesting that the stock is 67.547% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 1.938, suggesting its more volatile than the S&P 500 by 93.776%.
-
Which is a Better Dividend Stock CLRB or IMNN?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or IMNN?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Cellectar Biosciences, Inc.'s net income of -$4.4M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns CLRB or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of -255.85%. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CLRB or NBY?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1359.63%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -88.5%. Given that Cellectar Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cellectar Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CLRB or NBY More Risky?
Cellectar Biosciences, Inc. has a beta of 0.325, which suggesting that the stock is 67.547% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock CLRB or NBY?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or NBY?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cellectar Biosciences, Inc.'s net income of -$4.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 12.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 14.36x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M NBYNovaBay Pharmaceuticals, Inc.14.36x 12.41x $521K -$1.3M
-
Which has Higher Returns CLRB or PAVM?
PAVmed, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of -120220%. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat PAVmed, Inc.'s return on equity of 8.75%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M PAVMPAVmed, Inc.-1440% -$0.29 $35.1M -
What do Analysts Say About CLRB or PAVM?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1359.63%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 3983.1%. Given that PAVmed, Inc. has higher upside potential than Cellectar Biosciences, Inc., analysts believe PAVmed, Inc. is more attractive than Cellectar Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 PAVMPAVmed, Inc.1 0 0 -
Is CLRB or PAVM More Risky?
Cellectar Biosciences, Inc. has a beta of 0.325, which suggesting that the stock is 67.547% less volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.106, suggesting its more volatile than the S&P 500 by 10.577%.
-
Which is a Better Dividend Stock CLRB or PAVM?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or PAVM?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than PAVmed, Inc. quarterly revenues of $5K. Cellectar Biosciences, Inc.'s net income of -$4.4M is higher than PAVmed, Inc.'s net income of -$6M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 3,260.80x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M PAVMPAVmed, Inc.3,260.80x 0.30x $5K -$6M
-
Which has Higher Returns CLRB or PDSB?
PDS Biotechnology Corp. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of --. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat PDS Biotechnology Corp.'s return on equity of -196.47%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M -
What do Analysts Say About CLRB or PDSB?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1359.63%. On the other hand PDS Biotechnology Corp. has an analysts' consensus of $7.50 which suggests that it could grow by 726.36%. Given that Cellectar Biosciences, Inc. has higher upside potential than PDS Biotechnology Corp., analysts believe Cellectar Biosciences, Inc. is more attractive than PDS Biotechnology Corp..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 PDSBPDS Biotechnology Corp.3 0 0 -
Is CLRB or PDSB More Risky?
Cellectar Biosciences, Inc. has a beta of 0.325, which suggesting that the stock is 67.547% less volatile than S&P 500. In comparison PDS Biotechnology Corp. has a beta of 1.122, suggesting its more volatile than the S&P 500 by 12.163%.
-
Which is a Better Dividend Stock CLRB or PDSB?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. PDS Biotechnology Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or PDSB?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than PDS Biotechnology Corp. quarterly revenues of --. Cellectar Biosciences, Inc.'s net income of -$4.4M is higher than PDS Biotechnology Corp.'s net income of -$9M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while PDS Biotechnology Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus -- for PDS Biotechnology Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M PDSBPDS Biotechnology Corp.-- -- -- -$9M
-
Which has Higher Returns CLRB or PTN?
Palatin Technologies has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of --. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CLRB or PTN?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1359.63%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Cellectar Biosciences, Inc., analysts believe Palatin Technologies is more attractive than Cellectar Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 PTNPalatin Technologies0 0 0 -
Is CLRB or PTN More Risky?
Cellectar Biosciences, Inc. has a beta of 0.325, which suggesting that the stock is 67.547% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CLRB or PTN?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or PTN?
Cellectar Biosciences, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Cellectar Biosciences, Inc.'s net income of -$4.4M is higher than Palatin Technologies's net income of --. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M PTNPalatin Technologies-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
